Litcius/Paper detail

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Donn Colby, Michal Sarnecki, Dan H. Barouch, Somporn Tipsuk, Daniel J Stieh, Eugène Kroon, Alexandra Schuetz, Jintana Intasan, Carlo Sacdalan, Suteeraporn Pinyakorn, Pornsuk V. Grandin, Hongshuo Song, Sodsai Tovanabutra, Zhanna Shubin, Dohoon Kim, Dominic Paquin‐Proulx, Michael A. Eller, Rasmi Thomas, Mark de Souza, Lindsay Wieczorek, Victoria R. Polonis, Amélie Pagliuzza, Nicolas Chomont, Lauren Peter, Joseph P. Nkolola, Johan Vingerhoets, Carla Truyers, Maria Grazia Pau, Hanneke Schuitemaker, Nittaya Phanuphak, Nelson Michael, Merlin L. Robb, Frank Tomaka, Jintanat Ananworanich

2020Nature Medicine72 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicityMedicineHuman immunodeficiency virus (HIV)VirologyAntiretroviral therapyImmunologyViral loadImmune systemHIV Research and TreatmentVirology and Viral DiseasesHerpesvirus Infections and Treatments
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption | Litcius